After Neurocrine announced its Phase 2 SAVITRI dose-finding study of the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder, or MDD, met its primary and key secondary endpoints, RBC Capital said the results show “what appear to be clear signals of antidepressive activity” and “look potentially promising.” The firm, which believes Street expectations were “very low for this asset,” adds that there are “several missing pieces that preclude drawing definitive conclusions about ‘845’s potential.” RBC has a Sector Perform rating and $136 price target on Neurocrine Biosciences shares, which are up $7.22, or 5%, to $140.88 in morning trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine, Sentia Medical Sciences extend CRF research collaboration
- Voyager announces selection of development candidate for GBA1 Program
- Neurocrine initiates Phase 1 study of NBI-1065890
- Neurocrine price target raised to $158 from $148 at JPMorgan
- Spruce Biosciences downgraded to Market Perform from Outperform at Leerink